Author's response to reviews

Title: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

Authors:

  Yumi Asukai (yasukai@uk.imshealth.com)
  Amparo Valladares (valladares_maria_amparo@lilly.com)
  Carlos Camps (camps_car@gva.es)
  Eifiona Wood (ewood@uk.imshealth.com)
  Kaisa Taipale (taipale_kaisa@lilly.com)
  Jorge Arellano (arellano_jorge@lilly.com)
  Alejo Cassinello (cassinello_alejo@lilly.com)
  José Antonio Sacristán (sacristan_jose@lilly.com)
  Tatiana Dilla (dilla_tatiana@lilly.com)

Version: 8 Date: 28 January 2010

Author's response to reviews: see over
Melissa Norton  
Editor-in-Chief, BMC Series  
BioMed Central Ltd, Floor 6  
236 Gray’s Inn Road  
London WC1X 8HL  
United Kingdom

28 January 2010

Dear Ms Norton

I write on behalf of our research team to submit the final proofed manuscript for publication. All changes made in this version of the manuscript are typographical errors.

Yours Sincerely,

Yumi Asukai

On behalf of:

M. Amparo Valladares  
Carlos Camps  
Efíonia Wood  
Kaisa Taipale  
Jorge Arellano  
Alejo Cassinello  
José Antonio Sacristán  
Tatiana Dilla